| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lipoproteins, HDL | 48 | 2022 | 247 | 5.930 |
Why?
|
| Cholesterol | 66 | 2024 | 258 | 5.670 |
Why?
|
| ATP-Binding Cassette Transporters | 32 | 2013 | 58 | 5.110 |
Why?
|
| Liver | 41 | 2022 | 491 | 4.660 |
Why?
|
| Receptors, LDL | 24 | 2019 | 55 | 3.870 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 35 | 2016 | 39 | 3.870 |
Why?
|
| Triglycerides | 37 | 2022 | 234 | 3.690 |
Why?
|
| Apolipoprotein A-I | 41 | 2016 | 64 | 3.470 |
Why?
|
| Macrophages | 22 | 2019 | 164 | 2.870 |
Why?
|
| Animals | 157 | 2024 | 8165 | 2.780 |
Why?
|
| Atherosclerosis | 21 | 2021 | 806 | 2.760 |
Why?
|
| Mice | 78 | 2024 | 2544 | 2.590 |
Why?
|
| Hepatocytes | 8 | 2019 | 80 | 2.460 |
Why?
|
| Mice, Knockout | 50 | 2018 | 441 | 2.360 |
Why?
|
| Lipoproteins, VLDL | 16 | 2017 | 27 | 2.310 |
Why?
|
| Mice, Inbred C57BL | 48 | 2022 | 776 | 2.100 |
Why?
|
| Cholesterol, Dietary | 12 | 2018 | 40 | 1.900 |
Why?
|
| Plant Oils | 6 | 2015 | 17 | 1.870 |
Why?
|
| Apolipoproteins | 14 | 2016 | 193 | 1.840 |
Why?
|
| Apolipoproteins B | 23 | 2017 | 48 | 1.800 |
Why?
|
| Adipocytes | 5 | 2019 | 69 | 1.560 |
Why?
|
| Signal Transduction | 19 | 2024 | 716 | 1.560 |
Why?
|
| Cholesterol Esters | 28 | 2017 | 37 | 1.510 |
Why?
|
| Adipose Tissue | 8 | 2019 | 318 | 1.500 |
Why?
|
| Lipoproteins, LDL | 21 | 2010 | 83 | 1.470 |
Why?
|
| Sphingosine | 3 | 2019 | 14 | 1.430 |
Why?
|
| Lysophospholipids | 3 | 2019 | 26 | 1.410 |
Why?
|
| Lipoproteins | 26 | 2014 | 92 | 1.390 |
Why?
|
| Fish Oils | 18 | 2015 | 38 | 1.350 |
Why?
|
| Cholesterol, HDL | 24 | 2022 | 181 | 1.310 |
Why?
|
| Inflammation | 15 | 2017 | 500 | 1.270 |
Why?
|
| High-Density Lipoproteins, Pre-beta | 6 | 2010 | 6 | 1.260 |
Why?
|
| Apolipoproteins E | 16 | 2013 | 85 | 1.210 |
Why?
|
| Phosphatidylcholines | 13 | 2003 | 29 | 1.120 |
Why?
|
| Diet, Atherogenic | 16 | 2016 | 74 | 1.110 |
Why?
|
| Fatty Acids, Omega-3 | 7 | 2016 | 69 | 1.110 |
Why?
|
| Lipolysis | 4 | 2018 | 13 | 1.080 |
Why?
|
| Apolipoprotein B-100 | 6 | 2013 | 7 | 1.070 |
Why?
|
| Macrophages, Peritoneal | 6 | 2017 | 12 | 1.020 |
Why?
|
| Dietary Fats | 27 | 2014 | 98 | 1.020 |
Why?
|
| Gene Deletion | 6 | 2018 | 66 | 0.980 |
Why?
|
| Aortic Diseases | 5 | 2017 | 59 | 0.980 |
Why?
|
| Echium | 5 | 2015 | 11 | 0.960 |
Why?
|
| Obesity | 9 | 2022 | 1108 | 0.920 |
Why?
|
| Insulin Resistance | 9 | 2019 | 457 | 0.920 |
Why?
|
| Dietary Fats, Unsaturated | 12 | 2012 | 28 | 0.910 |
Why?
|
| Male | 73 | 2021 | 19434 | 0.900 |
Why?
|
| Arteriosclerosis | 11 | 2004 | 143 | 0.890 |
Why?
|
| Myeloid Cells | 3 | 2016 | 39 | 0.880 |
Why?
|
| Membrane Microdomains | 9 | 2017 | 22 | 0.880 |
Why?
|
| Lipid Metabolism | 10 | 2022 | 104 | 0.880 |
Why?
|
| Aorta | 7 | 2017 | 120 | 0.830 |
Why?
|
| Fatty Acids | 17 | 2012 | 100 | 0.810 |
Why?
|
| African Americans | 7 | 2019 | 1335 | 0.800 |
Why?
|
| Mice, Transgenic | 19 | 2013 | 254 | 0.800 |
Why?
|
| Gene Expression Regulation | 12 | 2016 | 478 | 0.780 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 1159 | 0.780 |
Why?
|
| Particle Size | 11 | 2013 | 47 | 0.760 |
Why?
|
| Monocytes | 8 | 2017 | 118 | 0.740 |
Why?
|
| Tangier Disease | 4 | 2011 | 5 | 0.730 |
Why?
|
| Humans | 77 | 2024 | 32284 | 0.730 |
Why?
|
| Lipids | 12 | 2014 | 250 | 0.660 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2024 | 1436 | 0.650 |
Why?
|
| Disease Models, Animal | 18 | 2021 | 1073 | 0.650 |
Why?
|
| Lipogenesis | 2 | 2017 | 18 | 0.640 |
Why?
|
| Carrier Proteins | 7 | 2016 | 148 | 0.610 |
Why?
|
| Gene Expression | 12 | 2013 | 345 | 0.610 |
Why?
|
| Fatty Acids, Unsaturated | 9 | 2012 | 43 | 0.590 |
Why?
|
| Fatty Liver | 3 | 2016 | 69 | 0.590 |
Why?
|
| Cells, Cultured | 17 | 2021 | 821 | 0.580 |
Why?
|
| Leukocytes | 2 | 2016 | 59 | 0.570 |
Why?
|
| Fatty Acid Desaturases | 2 | 2017 | 51 | 0.560 |
Why?
|
| Toll-Like Receptors | 3 | 2015 | 30 | 0.540 |
Why?
|
| Apolipoproteins A | 4 | 2016 | 27 | 0.540 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 35 | 0.530 |
Why?
|
| Tobacco | 1 | 2018 | 43 | 0.530 |
Why?
|
| Cholesterol, LDL | 14 | 2016 | 170 | 0.520 |
Why?
|
| Female | 37 | 2021 | 19954 | 0.510 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2020 | 821 | 0.490 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 17 | 0.490 |
Why?
|
| Lipocalins | 2 | 2013 | 6 | 0.480 |
Why?
|
| Cholesterol, VLDL | 7 | 2016 | 11 | 0.480 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 87 | 0.470 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2010 | 16 | 0.470 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2017 | 1052 | 0.470 |
Why?
|
| Nicotine | 1 | 2018 | 164 | 0.460 |
Why?
|
| Kidney | 4 | 2014 | 520 | 0.460 |
Why?
|
| Weight Loss | 2 | 2018 | 410 | 0.460 |
Why?
|
| Phospholipases A | 5 | 1999 | 29 | 0.450 |
Why?
|
| Toll-Like Receptor 4 | 4 | 2011 | 46 | 0.450 |
Why?
|
| Spleen | 3 | 2013 | 82 | 0.450 |
Why?
|
| Protein Sorting Signals | 1 | 2015 | 6 | 0.440 |
Why?
|
| Biological Transport | 9 | 2021 | 73 | 0.430 |
Why?
|
| Kidney Diseases | 3 | 2016 | 242 | 0.410 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 58 | 0.410 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 43 | 0.410 |
Why?
|
| Chemotaxis | 2 | 2012 | 15 | 0.390 |
Why?
|
| Genotype | 9 | 2019 | 706 | 0.380 |
Why?
|
| Recombinant Proteins | 10 | 2010 | 263 | 0.380 |
Why?
|
| Macaca fascicularis | 20 | 2000 | 542 | 0.370 |
Why?
|
| Listeria monocytogenes | 1 | 2012 | 8 | 0.370 |
Why?
|
| Cell Line | 9 | 2014 | 443 | 0.370 |
Why?
|
| T-Lymphocytes | 5 | 2017 | 138 | 0.370 |
Why?
|
| Hematopoiesis | 1 | 2012 | 29 | 0.360 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2012 | 6 | 0.360 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2012 | 3 | 0.360 |
Why?
|
| Inflammation Mediators | 5 | 2017 | 96 | 0.360 |
Why?
|
| Rats | 10 | 2017 | 1892 | 0.350 |
Why?
|
| Caveolae | 1 | 2011 | 4 | 0.350 |
Why?
|
| Dietary Supplements | 2 | 2012 | 187 | 0.340 |
Why?
|
| Phenotype | 8 | 2018 | 619 | 0.340 |
Why?
|
| Endothelial Cells | 3 | 2021 | 190 | 0.330 |
Why?
|
| Cell Proliferation | 7 | 2017 | 599 | 0.330 |
Why?
|
| Glutamic Acid | 2 | 2003 | 50 | 0.320 |
Why?
|
| Kinetics | 12 | 2016 | 248 | 0.320 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 149 | 0.320 |
Why?
|
| Graft Rejection | 1 | 2011 | 235 | 0.310 |
Why?
|
| Lipopolysaccharides | 7 | 2015 | 113 | 0.310 |
Why?
|
| Homeostasis | 5 | 2017 | 130 | 0.310 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2020 | 33 | 0.300 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 726 | 0.300 |
Why?
|
| Mutation | 4 | 2017 | 497 | 0.280 |
Why?
|
| Transfection | 11 | 2010 | 198 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 6 | 2011 | 189 | 0.280 |
Why?
|
| Sterol O-Acyltransferase | 7 | 2005 | 12 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2015 | 65 | 0.270 |
Why?
|
| Bone Marrow Transplantation | 5 | 2016 | 66 | 0.270 |
Why?
|
| Bile Acids and Salts | 4 | 2022 | 10 | 0.260 |
Why?
|
| Time Factors | 9 | 2016 | 2196 | 0.260 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 4 | 2024 | 15 | 0.260 |
Why?
|
| Alanine | 3 | 2014 | 30 | 0.260 |
Why?
|
| Weight Gain | 2 | 2018 | 103 | 0.260 |
Why?
|
| Fatty Acids, Omega-6 | 3 | 2016 | 36 | 0.250 |
Why?
|
| Phospholipids | 8 | 2014 | 32 | 0.250 |
Why?
|
| Enzyme Activation | 8 | 2020 | 133 | 0.250 |
Why?
|
| Lipase | 3 | 1999 | 30 | 0.240 |
Why?
|
| RNA, Messenger | 7 | 2014 | 499 | 0.240 |
Why?
|
| Ethinyl Estradiol | 3 | 2000 | 9 | 0.240 |
Why?
|
| Cell Size | 2 | 2018 | 40 | 0.240 |
Why?
|
| Lymphocyte Activation | 3 | 2017 | 94 | 0.240 |
Why?
|
| Immunity, Innate | 4 | 2016 | 81 | 0.230 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 368 | 0.230 |
Why?
|
| Intestinal Absorption | 4 | 2013 | 21 | 0.230 |
Why?
|
| Primates | 3 | 2022 | 128 | 0.220 |
Why?
|
| Coronary Artery Disease | 6 | 2000 | 427 | 0.220 |
Why?
|
| Up-Regulation | 3 | 2017 | 190 | 0.220 |
Why?
|
| Proteoglycans | 3 | 1994 | 34 | 0.220 |
Why?
|
| Point Mutation | 2 | 2001 | 29 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2015 | 252 | 0.210 |
Why?
|
| Intestinal Mucosa | 3 | 2013 | 75 | 0.210 |
Why?
|
| PPAR gamma | 4 | 2018 | 51 | 0.210 |
Why?
|
| COS Cells | 7 | 2003 | 31 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Protein Transport | 2 | 2017 | 80 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2012 | 213 | 0.200 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| MicroRNAs | 3 | 2016 | 181 | 0.200 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 22 | 0.200 |
Why?
|
| Prediabetic State | 1 | 2024 | 76 | 0.200 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2003 | 4 | 0.200 |
Why?
|
| Symporters | 1 | 2003 | 13 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Substrate Specificity | 5 | 2004 | 80 | 0.190 |
Why?
|
| Middle Aged | 12 | 2019 | 11843 | 0.190 |
Why?
|
| Apoptosis | 4 | 2017 | 367 | 0.190 |
Why?
|
| Orphan Nuclear Receptors | 5 | 2015 | 8 | 0.190 |
Why?
|
| Chemokines | 2 | 2013 | 34 | 0.190 |
Why?
|
| Chylomicrons | 4 | 1983 | 6 | 0.190 |
Why?
|
| Amino Acid Substitution | 4 | 2004 | 40 | 0.180 |
Why?
|
| Contraceptives, Oral, Combined | 3 | 2000 | 7 | 0.180 |
Why?
|
| Amino Acid Sequence | 6 | 2015 | 293 | 0.180 |
Why?
|
| Blotting, Western | 4 | 2019 | 297 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 82 | 0.180 |
Why?
|
| Centrifugation, Density Gradient | 7 | 2010 | 12 | 0.180 |
Why?
|
| Insulin | 2 | 2018 | 359 | 0.170 |
Why?
|
| 3T3-L1 Cells | 2 | 2018 | 6 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Body Composition | 1 | 2022 | 327 | 0.160 |
Why?
|
| NF-kappa B | 3 | 2010 | 83 | 0.160 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 11 | 0.160 |
Why?
|
| Estradiol Congeners | 1 | 2000 | 3 | 0.160 |
Why?
|
| Levonorgestrel | 1 | 2000 | 3 | 0.160 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 16 | 0.160 |
Why?
|
| Progesterone Congeners | 1 | 2000 | 22 | 0.160 |
Why?
|
| Hypercholesterolemia | 5 | 2016 | 72 | 0.160 |
Why?
|
| Membrane Fluidity | 1 | 2000 | 2 | 0.160 |
Why?
|
| Fibroblasts | 3 | 1999 | 118 | 0.160 |
Why?
|
| DNA, Complementary | 3 | 2009 | 30 | 0.160 |
Why?
|
| Diabetic Nephropathies | 2 | 2013 | 222 | 0.160 |
Why?
|
| Protein Conformation | 6 | 2012 | 110 | 0.160 |
Why?
|
| Gene Silencing | 2 | 2017 | 45 | 0.160 |
Why?
|
| Cholesterol Ester Storage Disease | 1 | 1999 | 1 | 0.150 |
Why?
|
| Wolman Disease | 1 | 1999 | 2 | 0.150 |
Why?
|
| Cloning, Molecular | 4 | 2009 | 77 | 0.150 |
Why?
|
| CHO Cells | 4 | 2003 | 27 | 0.150 |
Why?
|
| Cricetinae | 4 | 2003 | 49 | 0.150 |
Why?
|
| Contraceptives, Oral | 2 | 1997 | 26 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 3 | 2017 | 33 | 0.150 |
Why?
|
| Cell Membrane | 3 | 2015 | 109 | 0.150 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2019 | 4 | 0.150 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2009 | 15 | 0.150 |
Why?
|
| Binding, Competitive | 4 | 2007 | 41 | 0.150 |
Why?
|
| Gene Targeting | 3 | 2010 | 15 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 246 | 0.140 |
Why?
|
| Oleic Acids | 2 | 1992 | 9 | 0.140 |
Why?
|
| RNA | 2 | 2013 | 94 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 322 | 0.140 |
Why?
|
| Macrophage Activation | 2 | 2017 | 11 | 0.140 |
Why?
|
| Glucose | 3 | 2008 | 158 | 0.140 |
Why?
|
| Phosphorylation | 3 | 2020 | 248 | 0.140 |
Why?
|
| Progesterone | 2 | 1996 | 78 | 0.140 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 6 | 0.140 |
Why?
|
| Arteries | 4 | 1994 | 75 | 0.130 |
Why?
|
| Adipogenesis | 1 | 2018 | 30 | 0.130 |
Why?
|
| Calcium Channels | 1 | 2018 | 63 | 0.130 |
Why?
|
| Proteomics | 2 | 2015 | 96 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 64 | 0.130 |
Why?
|
| Progestins | 1 | 1997 | 27 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2017 | 144 | 0.130 |
Why?
|
| gamma-Linolenic Acid | 2 | 2015 | 11 | 0.130 |
Why?
|
| Dyslipidemias | 1 | 2017 | 59 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 52 | 0.130 |
Why?
|
| Onions | 1 | 2017 | 1 | 0.130 |
Why?
|
| Adipocytes, White | 1 | 2017 | 2 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 2 | 1996 | 216 | 0.130 |
Why?
|
| Quercetin | 1 | 2017 | 7 | 0.130 |
Why?
|
| Cytokines | 3 | 2012 | 236 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 892 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2004 | 64 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2018 | 154 | 0.120 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.120 |
Why?
|
| Mice, Obese | 2 | 2013 | 22 | 0.120 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 46 | 0.120 |
Why?
|
| Organ Specificity | 2 | 2014 | 79 | 0.120 |
Why?
|
| Neurons | 3 | 2009 | 484 | 0.120 |
Why?
|
| Cyclic AMP | 1 | 2016 | 54 | 0.120 |
Why?
|
| Bile | 2 | 2013 | 7 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2017 | 184 | 0.120 |
Why?
|
| beta-Cyclodextrins | 2 | 2008 | 4 | 0.120 |
Why?
|
| Adult | 7 | 2017 | 9263 | 0.120 |
Why?
|
| Estrogens | 1 | 1997 | 194 | 0.120 |
Why?
|
| Risk Factors | 5 | 2024 | 3938 | 0.120 |
Why?
|
| Peroxidase | 2 | 2014 | 27 | 0.120 |
Why?
|
| Lymph | 4 | 2006 | 4 | 0.120 |
Why?
|
| Ovariectomy | 2 | 1996 | 202 | 0.120 |
Why?
|
| Acute Disease | 1 | 2016 | 253 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 203 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 81 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 543 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2018 | 484 | 0.110 |
Why?
|
| Thymus Gland | 2 | 2012 | 15 | 0.110 |
Why?
|
| Coronary Vessels | 3 | 2017 | 173 | 0.110 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 1996 | 157 | 0.110 |
Why?
|
| Neutrophils | 2 | 2013 | 120 | 0.110 |
Why?
|
| Base Sequence | 3 | 2009 | 256 | 0.110 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 112 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2014 | 8 | 0.110 |
Why?
|
| Culture Media, Conditioned | 2 | 2012 | 50 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2013 | 153 | 0.110 |
Why?
|
| Mesangial Cells | 1 | 2014 | 9 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 72 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 122 | 0.100 |
Why?
|
| Hypertrophy | 1 | 2014 | 33 | 0.100 |
Why?
|
| Serum Amyloid A Protein | 2 | 1985 | 5 | 0.100 |
Why?
|
| Feces | 2 | 2013 | 50 | 0.100 |
Why?
|
| Amyloid | 2 | 1985 | 15 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 767 | 0.100 |
Why?
|
| Repressor Proteins | 1 | 2014 | 50 | 0.100 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 28 | 0.100 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 39 | 0.100 |
Why?
|
| Liposomes | 3 | 2001 | 35 | 0.100 |
Why?
|
| Protein Binding | 4 | 2016 | 243 | 0.100 |
Why?
|
| Cell Adhesion | 2 | 2014 | 95 | 0.100 |
Why?
|
| Phospholipases A2 | 3 | 1999 | 24 | 0.100 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 43 | 0.100 |
Why?
|
| Intracellular Space | 2 | 2013 | 17 | 0.100 |
Why?
|
| Calorimetry, Differential Scanning | 5 | 1996 | 13 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 164 | 0.100 |
Why?
|
| Interleukin-1 | 2 | 1994 | 48 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2015 | 243 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 555 | 0.100 |
Why?
|
| Adipose Tissue, White | 1 | 2013 | 6 | 0.100 |
Why?
|
| Epididymis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2001 | 93 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 3 | 0.100 |
Why?
|
| Membranes, Artificial | 1 | 1993 | 8 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 2 | 1994 | 25 | 0.100 |
Why?
|
| Vasculitis | 1 | 2013 | 26 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2008 | 709 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2012 | 3 | 0.090 |
Why?
|
| Macular Degeneration | 1 | 2013 | 25 | 0.090 |
Why?
|
| Antigens, Ly | 1 | 2012 | 7 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 27 | 0.090 |
Why?
|
| Adenoviridae | 2 | 2010 | 66 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 110 | 0.090 |
Why?
|
| Eicosanoids | 1 | 1992 | 9 | 0.090 |
Why?
|
| 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2012 | 1 | 0.090 |
Why?
|
| Kupffer Cells | 1 | 2012 | 10 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2012 | 56 | 0.090 |
Why?
|
| Testosterone | 1 | 1992 | 48 | 0.090 |
Why?
|
| Structure-Activity Relationship | 5 | 2003 | 88 | 0.090 |
Why?
|
| Chromatography, Gel | 3 | 2001 | 16 | 0.090 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 89 | 0.090 |
Why?
|
| Diet | 2 | 2011 | 382 | 0.090 |
Why?
|
| Foam Cells | 2 | 2013 | 9 | 0.080 |
Why?
|
| Esters | 2 | 2008 | 9 | 0.080 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 101 | 0.080 |
Why?
|
| Circular Dichroism | 4 | 1998 | 39 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 165 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2009 | 60 | 0.080 |
Why?
|
| Aging | 3 | 2012 | 941 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2002 | 470 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 2 | 2010 | 49 | 0.080 |
Why?
|
| Apolipoprotein A-II | 4 | 2001 | 5 | 0.080 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2010 | 7 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2009 | 109 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 302 | 0.080 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2010 | 2 | 0.080 |
Why?
|
| Ethynodiol Diacetate | 2 | 1990 | 2 | 0.080 |
Why?
|
| Norgestrel | 2 | 1990 | 3 | 0.080 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 9 | 0.080 |
Why?
|
| RNA Interference | 1 | 2010 | 77 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2014 | 151 | 0.080 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2009 | 2 | 0.080 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2009 | 19 | 0.080 |
Why?
|
| Genetic Engineering | 1 | 2009 | 22 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2009 | 5 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 863 | 0.080 |
Why?
|
| Carbonates | 1 | 2009 | 3 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 3 | 2014 | 246 | 0.080 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2009 | 8 | 0.080 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2009 | 16 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 26 | 0.080 |
Why?
|
| Alternative Splicing | 1 | 2009 | 32 | 0.080 |
Why?
|
| Transgenes | 1 | 2009 | 46 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2000 | 32 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 4 | 2001 | 43 | 0.070 |
Why?
|
| Molecular Weight | 6 | 1996 | 55 | 0.070 |
Why?
|
| Hypolipoproteinemias | 1 | 1989 | 1 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 46 | 0.070 |
Why?
|
| Sex Factors | 2 | 2018 | 656 | 0.070 |
Why?
|
| Mice, Mutant Strains | 3 | 2017 | 49 | 0.070 |
Why?
|
| Cercopithecus | 2 | 1986 | 2 | 0.070 |
Why?
|
| Fluorobenzenes | 1 | 2008 | 32 | 0.070 |
Why?
|
| Astrocytes | 1 | 2008 | 61 | 0.070 |
Why?
|
| Sterols | 1 | 2008 | 3 | 0.070 |
Why?
|
| Esterification | 2 | 1999 | 4 | 0.070 |
Why?
|
| Culture Media | 2 | 2007 | 47 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 32 | 0.070 |
Why?
|
| European Continental Ancestry Group | 3 | 2019 | 1076 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 85 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2008 | 85 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 64 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 77 | 0.070 |
Why?
|
| Trans Fatty Acids | 2 | 2004 | 10 | 0.070 |
Why?
|
| Epitopes | 2 | 2014 | 27 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2008 | 144 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 1998 | 58 | 0.060 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2007 | 13 | 0.060 |
Why?
|
| Coronary Disease | 3 | 1998 | 226 | 0.060 |
Why?
|
| Enzyme Induction | 2 | 2014 | 31 | 0.060 |
Why?
|
| Prognosis | 1 | 2011 | 1529 | 0.060 |
Why?
|
| Isomerism | 2 | 2000 | 6 | 0.060 |
Why?
|
| Random Allocation | 2 | 2014 | 246 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 154 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 238 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 46 | 0.060 |
Why?
|
| Benzylamines | 1 | 2006 | 6 | 0.060 |
Why?
|
| Benzoates | 1 | 2006 | 7 | 0.060 |
Why?
|
| Lipoprotein Lipase | 3 | 1995 | 13 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2238 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2014 | 452 | 0.060 |
Why?
|
| Models, Biological | 1 | 2008 | 403 | 0.060 |
Why?
|
| Oxidation-Reduction | 3 | 2014 | 255 | 0.060 |
Why?
|
| Scavenger Receptors, Class B | 2 | 2021 | 10 | 0.060 |
Why?
|
| Aged | 4 | 2017 | 10257 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 186 | 0.060 |
Why?
|
| Surface Properties | 2 | 1997 | 36 | 0.060 |
Why?
|
| Crosses, Genetic | 2 | 2003 | 21 | 0.060 |
Why?
|
| Perfusion | 4 | 2005 | 75 | 0.060 |
Why?
|
| Cell Survival | 2 | 2020 | 286 | 0.050 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 33 | 0.050 |
Why?
|
| Iodine Radioisotopes | 2 | 2001 | 22 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2015 | 146 | 0.050 |
Why?
|
| Species Specificity | 4 | 2009 | 98 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 590 | 0.050 |
Why?
|
| Static Electricity | 1 | 2003 | 13 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2017 | 24 | 0.050 |
Why?
|
| Sitosterols | 1 | 2003 | 2 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 858 | 0.050 |
Why?
|
| Chromatography, Affinity | 2 | 2001 | 15 | 0.050 |
Why?
|
| Serum Albumin, Bovine | 1 | 1983 | 11 | 0.050 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2003 | 2 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 27 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 23 | 0.050 |
Why?
|
| Protein Structure, Secondary | 3 | 1998 | 60 | 0.050 |
Why?
|
| Sodium | 1 | 2003 | 41 | 0.050 |
Why?
|
| Mutagenesis | 3 | 2014 | 34 | 0.050 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 2 | 2016 | 4 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2013 | 5 | 0.050 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 338 | 0.050 |
Why?
|
| Oleic Acid | 3 | 2003 | 7 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 325 | 0.050 |
Why?
|
| Alleles | 1 | 2003 | 250 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2014 | 137 | 0.050 |
Why?
|
| Ceramides | 2 | 2012 | 9 | 0.050 |
Why?
|
| Brain | 1 | 2009 | 966 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1299 | 0.040 |
Why?
|
| Isotope Labeling | 1 | 2002 | 14 | 0.040 |
Why?
|
| Permeability | 1 | 2021 | 11 | 0.040 |
Why?
|
| Cattle | 1 | 2021 | 118 | 0.040 |
Why?
|
| Protein Denaturation | 2 | 2001 | 16 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2003 | 122 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 390 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2008 | 896 | 0.040 |
Why?
|
| Chromatography, Thin Layer | 2 | 1992 | 9 | 0.040 |
Why?
|
| Phosphoserine | 1 | 2020 | 8 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 68 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 95 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2020 | 53 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 199 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 63 | 0.040 |
Why?
|
| Cysteine | 1 | 2001 | 145 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2020 | 285 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 1999 | 38 | 0.040 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1979 | 1 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 276 | 0.040 |
Why?
|
| Histidine | 1 | 1999 | 7 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Exons | 1 | 1999 | 52 | 0.040 |
Why?
|
| Thermodynamics | 2 | 1994 | 57 | 0.040 |
Why?
|
| Protein Engineering | 1 | 1999 | 19 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2010 | 131 | 0.040 |
Why?
|
| Baculoviridae | 2 | 1996 | 6 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 478 | 0.040 |
Why?
|
| Haplorhini | 4 | 1980 | 75 | 0.040 |
Why?
|
| Postmenopause | 2 | 2004 | 424 | 0.040 |
Why?
|
| Microscopy, Electron | 3 | 2005 | 44 | 0.040 |
Why?
|
| Hydrolysis | 1 | 1999 | 41 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 98 | 0.040 |
Why?
|
| Mitochondria | 1 | 2020 | 207 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 140 | 0.040 |
Why?
|
| Linoleic Acids | 2 | 1995 | 4 | 0.030 |
Why?
|
| Linoleic Acid | 2 | 1995 | 19 | 0.030 |
Why?
|
| Models, Chemical | 2 | 1999 | 33 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 126 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2017 | 9 | 0.030 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2009 | 8 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2017 | 39 | 0.030 |
Why?
|
| Linear Models | 1 | 1998 | 426 | 0.030 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2017 | 3 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 3521 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1997 | 11 | 0.030 |
Why?
|
| Sulfur Radioisotopes | 1 | 1997 | 8 | 0.030 |
Why?
|
| Histones | 1 | 2017 | 50 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1997 | 135 | 0.030 |
Why?
|
| Adipocytes, Brown | 1 | 2017 | 2 | 0.030 |
Why?
|
| Guanidines | 1 | 1997 | 7 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 23 | 0.030 |
Why?
|
| Glutamates | 1 | 1997 | 10 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 107 | 0.030 |
Why?
|
| Papio | 1 | 1997 | 78 | 0.030 |
Why?
|
| Infant | 1 | 1999 | 1024 | 0.030 |
Why?
|
| Egg Yolk | 1 | 1996 | 1 | 0.030 |
Why?
|
| Temperature | 1 | 1996 | 58 | 0.030 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 6 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2017 | 61 | 0.030 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 1 | 1996 | 1 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 1996 | 16 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 33 | 0.030 |
Why?
|
| Tunicamycin | 1 | 1996 | 6 | 0.030 |
Why?
|
| Glycosylation | 1 | 1996 | 15 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 84 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2016 | 42 | 0.030 |
Why?
|
| Amidohydrolases | 1 | 1996 | 9 | 0.030 |
Why?
|
| Neuraminidase | 1 | 1996 | 8 | 0.030 |
Why?
|
| Protein Precursors | 1 | 1996 | 24 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 14 | 0.030 |
Why?
|
| Tamoxifen | 1 | 1996 | 59 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1996 | 273 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 57 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 114 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1996 | 201 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 1995 | 10 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 36 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 22 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 293 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 1995 | 2 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 1995 | 21 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 90 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 960 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 55 | 0.030 |
Why?
|
| Proteome | 1 | 2015 | 41 | 0.030 |
Why?
|
| Safflower Oil | 1 | 1994 | 1 | 0.030 |
Why?
|
| Azacitidine | 1 | 2014 | 27 | 0.030 |
Why?
|
| Podocytes | 1 | 2014 | 19 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 93 | 0.030 |
Why?
|
| Immunosorbent Techniques | 1 | 1994 | 1 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 33 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 257 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 40 | 0.030 |
Why?
|
| Cell Movement | 1 | 2014 | 165 | 0.030 |
Why?
|
| Vitamin E | 1 | 1993 | 15 | 0.030 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2013 | 9 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 249 | 0.020 |
Why?
|
| Child | 1 | 1999 | 2446 | 0.020 |
Why?
|
| Animal Feed | 1 | 2013 | 23 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 32 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 123 | 0.020 |
Why?
|
| Body Weight | 2 | 1995 | 323 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2010 | 222 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 54 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 101 | 0.020 |
Why?
|
| Indians, North American | 1 | 2013 | 75 | 0.020 |
Why?
|
| Ethinyl Estradiol-Norgestrel Combination | 2 | 1990 | 3 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 455 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2012 | 22 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 75 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 60 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 98 | 0.020 |
Why?
|
| Sphingomyelins | 1 | 2012 | 8 | 0.020 |
Why?
|
| Antibodies | 1 | 2012 | 55 | 0.020 |
Why?
|
| Thiobarbiturates | 1 | 1992 | 1 | 0.020 |
Why?
|
| Drug Combinations | 2 | 1990 | 102 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 544 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1992 | 6 | 0.020 |
Why?
|
| Thromboxane B2 | 1 | 1992 | 4 | 0.020 |
Why?
|
| Thromboxane A2 | 1 | 1992 | 4 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1992 | 3 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1992 | 83 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2012 | 6 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2012 | 18 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 41 | 0.020 |
Why?
|
| Endotoxins | 1 | 2012 | 36 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1991 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 221 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1993 | 255 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 106 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 760 | 0.020 |
Why?
|
| Secretory Pathway | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2010 | 29 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1990 | 58 | 0.020 |
Why?
|
| E-Selectin | 1 | 2010 | 20 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 40 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 22 | 0.020 |
Why?
|
| Estradiol | 1 | 1990 | 139 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2009 | 24 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 50 | 0.020 |
Why?
|
| Solubility | 2 | 2001 | 39 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 42 | 0.020 |
Why?
|
| Plasmids | 1 | 2009 | 53 | 0.020 |
Why?
|
| Calcium | 1 | 1991 | 337 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2009 | 48 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Amino Acids | 2 | 1980 | 52 | 0.020 |
Why?
|
| Tretinoin | 1 | 2009 | 33 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2009 | 18 | 0.020 |
Why?
|
| Drosophila | 1 | 2009 | 35 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1990 | 116 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 30 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 184 | 0.020 |
Why?
|
| Stem Cells | 1 | 2012 | 317 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 47 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1989 | 9 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4079 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2009 | 66 | 0.020 |
Why?
|
| Behavior | 1 | 2009 | 29 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2009 | 83 | 0.020 |
Why?
|
| Mevalonic Acid | 1 | 2008 | 1 | 0.020 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2008 | 1 | 0.020 |
Why?
|
| rab3A GTP-Binding Protein | 1 | 2008 | 1 | 0.020 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Monoterpenes | 1 | 2008 | 3 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2008 | 7 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cyclohexenes | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 111 | 0.020 |
Why?
|
| Leucine | 1 | 2008 | 23 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 74 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 39 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 43 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 69 | 0.020 |
Why?
|
| Swine | 1 | 1989 | 229 | 0.020 |
Why?
|
| Synapses | 1 | 2009 | 87 | 0.020 |
Why?
|
| Linseed Oil | 1 | 2008 | 2 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 550 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 152 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 172 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1998 | 7 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 3896 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 87 | 0.020 |
Why?
|
| Catalysis | 1 | 2007 | 71 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 520 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1984 | 67 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2007 | 204 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2006 | 5 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 411 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 64 | 0.010 |
Why?
|
| Intestines | 1 | 2006 | 66 | 0.010 |
Why?
|
| Asthma | 1 | 2008 | 262 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 1985 | 4 | 0.010 |
Why?
|
| Colloids | 1 | 1984 | 3 | 0.010 |
Why?
|
| Micelles | 1 | 1984 | 7 | 0.010 |
Why?
|
| Margarine | 1 | 2004 | 1 | 0.010 |
Why?
|
| Butter | 1 | 2004 | 2 | 0.010 |
Why?
|
| Soybean Oil | 1 | 2004 | 9 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 96 | 0.010 |
Why?
|
| Cyclodextrins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Apolipoprotein E3 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Microsomes | 1 | 2003 | 12 | 0.010 |
Why?
|
| Tritium | 1 | 2003 | 19 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1983 | 8 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1983 | 7 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2003 | 56 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 566 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1983 | 179 | 0.010 |
Why?
|
| X-Ray Diffraction | 1 | 1981 | 4 | 0.010 |
Why?
|
| Dimyristoylphosphatidylcholine | 1 | 2001 | 6 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2001 | 6 | 0.010 |
Why?
|
| Buffers | 1 | 2001 | 11 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 143 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 81 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2003 | 417 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1980 | 1 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1980 | 4 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1980 | 5 | 0.010 |
Why?
|
| Sialic Acids | 1 | 1979 | 1 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1999 | 16 | 0.010 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 1979 | 20 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 3 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1994 | 1 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1994 | 9 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1994 | 4 | 0.010 |
Why?
|
| Lipoproteins, IDL | 1 | 1993 | 1 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 1993 | 9 | 0.010 |
Why?
|
| Dermatan Sulfate | 1 | 1993 | 2 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 1993 | 23 | 0.010 |
Why?
|
| Heparin | 1 | 1993 | 65 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1991 | 173 | 0.000 |
Why?
|
| Densitometry | 1 | 1986 | 4 | 0.000 |
Why?
|
| Chemistry | 1 | 1985 | 2 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1985 | 5 | 0.000 |
Why?
|
| Membranes | 1 | 1984 | 12 | 0.000 |
Why?
|
| Ions | 1 | 1984 | 15 | 0.000 |
Why?
|
| Albumins | 1 | 1984 | 42 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1985 | 159 | 0.000 |
Why?
|